Mizuno will release this April its Wave Enforce Tour AC, the ideal shoe for powerful players who love to dictate points from the baseline,
The Enforce Tour is designed for maximum impact from the baseline and is the most comfortable, durable, and stable model in the brand’s line, according to Dave Dorsey, Mizuno tennis sales manager.
In contrast, the brand’s previous release, the Wave Exceed Tour, is more for players who attack from all over the court.
While it is a little heavier than the Exceed Tour, it’s one of the lightest, shoes in the baseline segment.
The Wave Enforce Tour AC is also equipped with lateral stability and shock absorption tech.
The Mizuno Enerzy Core material is the densest Enerzy material that comes from the Mizuno line of cushioning, a product first introduced in the brand's running lines. While heavier than the other Enerzy materials, the rebound and comfort levels are greater, leading to improved step-in comfort.


Asian Stocks Slip as Iran Tensions, Samsung Weakness and Fed Caution Weigh on Markets
Apple Eyes U.S. Formula 1 Broadcast Rights in Major Sports Streaming Push
Germany Seen Gaining as U.S. China-Built Ship Fees Reshape Trade
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Trump Booed at Club World Cup Final, Praises Pele as Soccer’s GOAT
Asian Stocks Rise as AI Chip Rally Offsets Middle East Tensions
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest
US Launches New Iran Strikes as Strait of Hormuz Conflict Escalates, Oil Prices Rise
Japan Wholesale Inflation Jumps as Energy Shock Drives Import Costs Higher
Bernstein Raises 2026 Nickel Price Forecast as Indonesia Tightens Supply
Gold Price Climbs Over 1% as Dollar Weakens, Fed Rate Debate and Iran Tensions Remain in Focus
Trump Signs Executive Order Targeting Big-Money College Athlete Payouts
Native American Groups Slam Trump’s Call to Restore Redskins Name
FIFA Faces Investigation Over 2026 World Cup Ticket Pricing and Seat Allocation Issues
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



